EBITDA

A new 'Street Date Program' from Follett aims to get hot new releases on library shelves on day one, addressing a major industry challenge.

A new book argues modern genomics is stuck on a 'parts list.' Can an architectural approach called 'Deterministic Convergence' build a better future for health?

Becker and the University of Missouri launch a new course to address critical knowledge gaps, aiming to better prepare candidates for CPA and CMA exams.

A new platform aims to replace AI's legal battles over content with a marketplace for consent, control, and compensation for creators and individuals.

A new partnership between distributor Semitech and NVE Corp. aims to ease sourcing for vital digital isolators, boosting stability for key industries.

A new startup is rewiring travel by plugging hotels directly into ChatGPT, challenging the dominance of OTAs and promising better deals for travelers.

AV Access launches the iDock B23, an 8K triple-monitor KVM dock aiming to unify high-refresh-rate gaming and professional workflows in a single device.

Aequify's new AI platform automates complex data collection, promising to free up tax advisors for higher-value, year-round client guidance.

A unique culinary event pairs a top chef with a non-profit's organic farm, serving up more than just a meal to support children and veterans.

Opus promotes Pete Conlon and Su O'Sullivan, redefining its CFO role to aggressively pursue capital and navigate a complex real estate market.

The memory chip maker secures a major defense contract, highlighting the critical role of its MRAM tech and U.S.-based manufacturing for national security.

The expanded partnership integrates real-time case tracking and post-sale servicing into Hexure's FireLight, aiming to create a single, unified workflow.

A new collaboration leverages a vast cord blood bank and advanced AI to create off-the-shelf cell therapies, promising a new era in regenerative medicine.

BsStrategy's latest platform update signals a major shift in AI finance, where robust infrastructure and risk control are eclipsing the hunt for magic algorithms.

With fresh capital, the Swedish biotech is scaling its revolutionary platform that decodes cellular communication, fueling a major US expansion.

New pre-clinical data shows engineered immune cells (iMacrophages) can effectively target and destroy ovarian tumors, offering hope for a new treatment era.

Biotech firm Scribe Therapeutics, co-founded by a Nobel laureate, is pioneering a new gene therapy for high cholesterol that silences genes, not cuts them.

After a record 2025 but a mixed Q4, the aerospace supplier's upcoming earnings will reveal its resilience against renewed supply chain disruptions.

With its third acquisition in 10 months, Pinnaql, backed by 3 Boomerang Capital, is rapidly building a one-stop-shop for life sciences advisory.

After dominating the utility sector, tax software firm Lucasys is now signing major oil & gas clients, signaling a strategic shake-up in energy finance.